Stockscreener 앱 받기
2.22
3.26%
0.07
시간 외 거래:
2.20
-0.02
-0.90%
전일 마감가:
$2.15
열려 있는:
$2.1
하루 거래량:
3.36M
Relative Volume:
0.66
시가총액:
$498.90M
수익:
$22,000
순이익/손실:
$-190.89M
주가수익비율:
-2.557
EPS:
-0.8682
순현금흐름:
$-149.63M
1주 성능:
-10.12%
1개월 성능:
+4.23%
6개월 성능:
+91.38%
1년 성능:
+31.36%
1일 변동 폭
$2.09
$2.269
1주일 범위
$2.09
$2.73
52주 변동 폭
$0.8621
$2.80
Allogene Therapeutics Inc Stock (ALLO) Company Profile
명칭
Allogene Therapeutics Inc
전화
(650) 457-2700
주소
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
2.22 | 483.17M | 22,000 | -190.89M | -149.63M | -0.8682 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-09 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-10-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-05-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | 재개 | Oppenheimer | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-01-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-08-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-28 | 재확인 | B. Riley Securities | Buy |
| 2021-10-20 | 개시 | Cowen | Outperform |
| 2021-10-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-10-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | 재개 | Jefferies | Buy |
| 2021-05-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-14 | 개시 | B. Riley Securities | Buy |
| 2021-01-26 | 업그레이드 | Stifel | Hold → Buy |
| 2020-12-10 | 재개 | H.C. Wainwright | Buy |
| 2020-11-24 | 개시 | BofA Securities | Buy |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-06-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-19 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2020-05-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-14 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-04-13 | 개시 | SunTrust | Buy |
| 2020-03-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-24 | 개시 | Berenberg | Hold |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-05 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Neutral |
| 2019-05-23 | 개시 | Stifel | Hold |
| 2019-03-29 | 개시 | Piper Jaffray | Overweight |
모두보기
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
Allogene Therapeutics (NASDAQ:ALLO) SVP Sells $11,942.45 in Stock - MarketBeat
David Chang Sells 47,763 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock - MarketBeat
Allogene (NASDAQ: ALLO) SVP share sale funds tax withholding - Stock Titan
Allogene (ALLO) CEO executes 47,763-share tax sell-to-cover transaction - Stock Titan
Allogene Therapeutics targets new approach to autoimmune conditions with ALLO-329 - Traders Union
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 earnings call transcript - MSN
Allogene Therapeutics (NASDAQ:ALLO) Stock Price Down 5.1%Time to Sell? - MarketBeat
Allogene targets pivotal ALPHA3 data in April and extends cash runway into 2028 while prioritizing scalable CAR T programs - MSN
Take the Zacks approach to beat the markets: Starbucks, Amgen, Allogene in focus - MSN
Allogene Therapeutics (NASDAQ: ALLO) proposes sale of 4,835 shares - Stock Titan
Citizens reiterates Allogene stock rating on pipeline progress - Investing.com
Citizens reiterates Allogene stock rating on pipeline progress By Investing.com - Investing.com UK
Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Expands By 19.8% - MarketBeat
Allogene Therapeutics Banks on 2026 Trial Catalysts - The Globe and Mail
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com
Analysts Are Bullish on Top Healthcare Stocks: Equillium (EQ), Qiagen (QGEN) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Allogene Therapeutics (ALLO) - The Globe and Mail
Canaccord Genuity Group Reiterates Buy Rating for Allogene Therapeutics (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug - AOL.com
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision - AOL.com
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - The Globe and Mail
El Pollo Loco Posts Upbeat Q4 Results, Joins Kyivstar Group, American Public Education And Other Big Stocks Moving Higher On Friday - Benzinga
Allogene Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Q32 Bio (QTTB) - The Globe and Mail
Allogene Therapeutics (ALLO) Projects Key Milestones for 2026 - GuruFocus
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update - Sahm
Allogene Therapeutics 2025 Annual Report: Advancing Allogeneic CAR T Cell Therapies for Cancer and Autoimmune Diseases - Minichart
Allogene Therapeutics Inc (ALLO) Q4 2025 Earnings Call Highlight - GuruFocus
Allogene Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Allogene Therapeutics beats Q4 2025 EPS forecast By Investing.com - Investing.com India
Earnings call transcript: Allogene Therapeutics beats Q4 2025 EPS forecast - Investing.com South Africa
Allogene (ALLO) Q4 2025 Earnings Call Transcript - The Globe and Mail
Rate Cut: Will Allogene Therapeutics Inc benefit from geopolitical trends2026 Drop Watch & Weekly Momentum Picks - baoquankhu1.vn
Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Narrower-Than-Expected Q4 Loss, Highlights Key 2026 Clinical Catalysts - ChartMill
Allogene Therapeutics (NASDAQ:ALLO) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
ALLOGENE THERAPEUTICS ($ALLO) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative
Allogene Therapeutics Q4 net loss narrows - TradingView
Allogene Therapeutics: Fourth Quarter Earnings Overview - Bitget
Allogene Therapeutics: Q4 Earnings Snapshot - Barchart
Allogene Therapeutics 2025 10-K: Net loss $190.9M, EPS $(0.87); runway into Q1 2028 - TradingView
Allogene Therapeutics (NASDAQ: ALLO) outlines allogeneic CAR T plans and risks - Stock Titan
Allogene (NASDAQ: ALLO) details 2025 loss, pipeline data milestones and cash runway - Stock Titan
Cancer and autoimmune push: inside Allogene’s 2026 CAR T trials - Stock Titan
Allogene Therapeutics advances ALLO-329 using Dagger technology to target autoimmune disease - Traders Union
Aug Shorts: What are the future prospects of Allogene Therapeutics IncAnalyst Downgrade & Entry Point Confirmation Alerts - baoquankhu1.vn
Allogene Therapeutics Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - AOL.com
Allogene Therapeutics (NASDAQ:ALLO) Shares Up 7.4%Here's Why - MarketBeat
Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus - TradingView
Allogene Therapeutics Inc (ALLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):